Dr. Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
Neoplasic Diseases
Milwaukee, WI 53226Phone+1 414-805-4600
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2012 - 2015
Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
University of Illinois College of MedicineClass of 2008
Certifications & Licensure
WI State Medical License 2015 - 2025
PA State Medical License 2012 - 2016
IL State Medical License 2011 - 2014
MA State Medical License 2010 - 2011- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Start of enrollment: 2017 Oct 16
- Long-term Follow-up Study of Patients Receiving CAR-T Cells Start of enrollment: 2017 Dec 01
- Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Start of enrollment: 2018 Feb 22
- Join now to see all
Publications & Presentations
PubMed
- 169 citationsRuxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trialMadan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah
Blood. 2020-05-14 - 29 citationsVedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Yi-Bin Chen, Nirav N. Shah, Anne S. Renteria, Corey Cutler, Johan Jansson
Blood Advances. 2019-12-10 - 65 citationsEfficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Tran...Sameem Abedin, Edward J. Mckenna, Saurabh Chhabra, Marcelo C. Pasquini, Nirav N. Shah
Biology of Blood and Marrow Transplantation. 2019-08-01
Lectures
- Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
- Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Zamtocabtagene Autoleucel Produces High ORR in Relapsed/Refractory DLBCLFebruary 21st, 2023- Fludarabine Shortage Requires Flexibility, Alternative Approaches for CAR-T and HSCTNovember 23rd, 2022
- CAR-T Therapy Ushering in a New Era of Precision Medicine for Patients with Chronic Lymphocytic LeukemiaMarch 11th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
